Prof. Zhi-Ming Shao, distinguished professor of Fudan University, is one of the first batch of distinguished professor of Chang Jiang Scholars. He presently serves as the director of Fudan University Cancer Institute and Breast Cancer Institute; chairman of Department of Surgery and Department of Breast Surgery in Fudan University Cancer Hospital; Honorary chairman of Breast Cancer Society, Chinese Anti-Cancer Association; Vice chairman of oncology branch committee, Chinese Medical Association; Honorary chairman of Breast Cancer Society, Shanghai Anti-Cancer Association; Chairman of oncology branch committee, Shanghai Medical Association; Chairman of the Eighth Asian Breast Cancer Society, and member of the St. Gallen international breast cancer consensus panel.

Prof. Shao engages in clinical and basic research for breast cancer. He established an early screening and diagnosis process for the Chinese population, investigated molecular subtyping of triple-negative breast cancer, and carried out clinical trials to improve the prognosis of breast cancer patients. His researches mainly focus on breast cancer translational research and mechanisms of metastasis of breast cancer. He has published nearly 500 papers about breast cancer research, and over 400 of which are indexed by SCI, including Cancer Cell, J Clin Oncol and JAMA Oncol, and have been cited for more than 6000 times by the world’s medical literature. Dr. Shao has been awarded with Prize of Science and Technology Progress of Ministry of Health, Grade I; Prize of Science and Technology Progress of Shanghai Government, Grade I, II and III; National Prize of Science and Technology Progress, Grade II; and Prize of Science and Technology Progress of Ministry of Education, Grade I, II. He was chosen as leader of selected innovative team of the Ministry of Education, Shanghai Key Laboratory of Breast Malignancy Tumor, Shanghai Municipal Health Commission Type B Program of the Priority Project of Clinical Medical Centers, and the Shanghai Joint Research Project of Major Diseases. He hosted and actualized in over 30 key research projects including National Excellent Youth Foundation, National Science Foundation, Key Project of National 10th 5-year Plan, Priority project on clinical medicine of Ministry of Health, 211 Project phase II, 985 Project, 973 Project, and other provincial or ministerial projects.

Research Focus:

Researches mainly focus on breast cancer translational research and mechanisms of metastasis of breast cancer.

Selected Publications:

1.Jin X^#, Zhou YF^#, Ma D^#, Zhao S^#, Lin CJ^#, Xiao Y, Fu T, Liu CL., Chen YY, Xiao WX, Liu YQ, Chen QW, Yu Y, Shi LM, Shi JX., Huang W, Robertson JFR., Jiang YZ^*, Shao ZM^*. Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nat Genet. 2023 Oct; 55(10):1696-1708.

2.Xiao Y, Yu TJ, Xu Y, Ding R, Wang YP, Jiang YZ, Shao ZM*. Emerging therapies in cancer metabolism. Cell Metab.2023 Aug 8; 35(8):1283-1303.

3.Liu Y^#, Zhu XZ^#, Xiao Y^#, Wu SY^#, Zuo WJ, Yu Q, Cao AY, Li JJ, Yu KD, Liu GY, Wu J, Sun T, Cui JW, Lv Z, Li HP, Zhu XY, Jiang YZ^*, Wang ZH^*, Shao ZM*. Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. Cell Res. 2023 May; 33(5):389-402.

4.Yang F^#, Xiao Y^{#, *}, Ding JH, Jin X, Ma D, Li DQ, Shi JX, Huang W, Wang YP, Jiang YZ^*, Shao ZM^*. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 2023 Jan 08; 35(1):84-100.e8.

5.Yang YS^#, Jin X^#, Li Q, Chen YY, Chen FF, Zhang HN, Su Y, Xiao Y, Di GH, Jiang YZ*, Huang SL*, Shao ZM^*. Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression. Proc Natl Acad Sci U S A. 2022 Nov 16; 119(46):e2207201119.

6.Wang H^#, Rong XY^#, Zhao G^#, Zhou YF^#, Xiao Y, Ma D, Jin X, Wu YL, Yan YC, Yang H, Zhou Y, Qian MN, Niu C, Hu X, Li DQ, Liu QY, Wen YM, Jiang YZ^*, Zhao C^*, Shao ZM^*. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. Cell Metab. 2022 Apr 5; 34(4):581-594.e8.

7.Gong Y^#, Ji P^#, Yang YS^#, Xie S, Yu TJ, Xiao Y, Jin ML, Ma D, Guo LW, Pei YC, Chai WJ, Li DQ, Bai F, Bertucci F, Hu X*, Jiang YZ*, Shao ZM*. Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Cell Metab. 2021 Jan 5; 33(1):51-64.e9.

8.Yu KD^#*, Ye FG^#, He M^#, Fan L^#, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM*. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1; 6(9):1390-1396.

9.Li JJ^#, Yu KD^#, Pang D, Wang CQ, Jiang J, Yang SS, Liu YJ, Fu PF, Sheng Y, Zhang GJ, Cao YL, He Q, Cui SD, Wang XJ, Ren GS, Li XZ, Yu SY, Liu PX, Qu X, Tang JH, Wang OC, Fan ZM, Jiang GQ, Zhang J, Wang JD, Zhang HW, Wang S, Zhang JG, Jin F, Rao NY, Ma BL, He PQ, Xu BH, Zhuang ZG, Wang JF, Sun Q, Guo XF, Mo M, Shao ZM*. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. J Clin Oncol. 2020 Jun 1; 38(16):1774-1784.

10.Jiang YZ^#, Ma D^#, Suo C^#, Shi JX^#, Xue MZ^#, Hu X^#, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng YT, Li XN, Zhang CH, Hu PC, Zhang J, Hua Q, Zhang JY, Hou WW, Ren LY, Bao D, Li BY, Yang JC, Yao L, Zuo WJ, Zhao S, Gong Y, Ren YX, Zhao YX, Yang YS, Niu ZM, Cao ZG, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li DQ, Wang P*, Shi LM*, Huang W*, Shao ZM*. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019 Mar 18; 35(3):428-440.